WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

, /PRNewswire/ — WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced updated preclinical data that validates its off-the-shelf fratricide-resistant CAR-T platform. The data from this study, which was led by researchers from the in , demonstrated efficacy in preclinical mouse models and was presented in an oral and poster presentation at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition in . ST. LOUIS Dec. 3, 2018 Washington University St. Louis San Diego “An off-the-shelf allogeneic CAR-T cell therapy could be a game changer for the treatment of T-cell cancers,” says , Ph.D., CEO and President of WUGEN. “These presentations provide insight into how to solve the challenges and limitations in current CAR-T therapies. The compelling findings advance our understanding of how to improve patient outcomes for those with T cell malignancies.” John McKearn Modeling Sézary Syndrome for Immunophenotyping and Anti-Tumor Effect of UCART and Long Acting Interleukin-7 Combination Therapy ( ) Abstract #340 Overview and results, presented by , Ph.D., of , include: Karl W. Staser Washington University St. Louis These preclinical data validate the use of allogeneic “off-the-shelf” adoptive immunotherapy for the treatment of Sézary syndrome (SS), while demonstrating dramatic enhancement of CAR-T efficacy using a dose-adjustable, clinic-ready long-acting interleukin-7 agonist (NT-I7) given in an adjuvant setting. UCART2-treated mice showed dramatically reduced tumor burden as compared to control UCART19-treated mice. UCART2-treated mice survived ~40 days as compared to ~21 days in mice treated with UCART19. Remarkably, UCART2-treated mice receiving NT-I7 showed complete tumor clearance with 100% of UCART2- and NT-I7-treated mice surviving beyond 150 days. WUGEN plans to initiate IND-enabling studies of UCART2. A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates UCART Proliferation, Differentiation, and Tumor Killing ( ) Abstract #2199 Overview and results, presented by , Ph.D., of , include: Matt L. Cooper Washington University St. Louis Suboptimal CAR-T persistence and tumor killing permit tumor cell escape and, ultimately, disease relapse in current clinical practice. NT-I7 was demonstrated to dramatically enhance gene modified T-cell proliferation, persistence and tumor killing in vivo, resulting in enhanced survival, providing a tunable clinic-ready adjuvant for reversing suboptimal CAR-T activity in vivo. Mice treated with UCART19 alone survived 33 days, mice treated with UCART19 and NT-I7 were alive at 80 days, with no mouse showing signs of graft vs. host disease (p<0.0001, UCART19+NT-I7 vs. UCART19). Analyses of the blood, bone marrow, and spleens of mice revealed an up to ~8000-fold increase in UCART19 cells in NT-I7-treated mice four weeks post UCART19 infusion. WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an “off-the-shelf” fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN’s state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from in . For more information please visit . About WUGEN Washington University St. Louis wugen.com or Russo Partners 858-717-2310 212-845-4272 For media inquiries contact: David Schull Travis Kruse [email protected] [email protected] SOURCE WUGEN Inc. Related Links https://wugen.com

The release as fetched from its publisher. wugen.com ↗